

Contents

| | |
|--|-------------|
| Abbreviations | xiii |
| Chapter 1 Introduction | 01 |
| 1.1 Metals in Medicine – A Historical Perspective | 01 |
| 1.2 Metals and Human Biochemistry | 03 |
| 1.3 Metallopharmaceuticals | 06 |
| 1.3.1 General Requirements | 06 |
| 1.3.2 Structure-Activity Relationships | 09 |
| 1.3.3 Clinical Trials | 11 |
| 1.4 The Special Properties of Metals | 11 |
| 1.4.1 Comparison with Organic and Biological Compounds | 11 |
| 1.4.2 Coordination Chemistry | 14 |
| | |
| Chapter 2 The Chemistry of Metals in a Nutshell | 15 |
| 2.1 The Structure of Materials | 15 |
| 2.1.1 States of Matter | 15 |
| 2.1.2 Chemical Elements | 16 |
| 2.1.3 Chemical Compounds | 20 |
| 2.2 The Structures and Properties of Atoms | 24 |
| 2.2.1 Electron Configurations | 24 |
| 2.2.2 The Spatial Distribution of Electrons in Atoms | 26 |
| 2.2.3 The Electronic Properties of Atoms and Ions | 35 |
| 2.2.4 The Radii of Atoms and Ions | 37 |
| 2.3 The Formation of Compounds | 38 |
| 2.3.1 Chemical Bonds | 38 |
| 2.3.2 The Ionic Bond | 39 |
| 2.3.3 The Covalent Bond | 40 |
| 2.3.4 The Coordinate Bond | 42 |
| 2.3.5 Polarity in Bonding | 44 |

| | | |
|--------------------------------------|---|------------|
| 2.4 | The Chemistry of Metals – An Overview | 49 |
| 2.4.1 | The Oxidation Numbers and Electron Configurations of Metal Ions | 49 |
| 2.4.2 | The Structures of Metal Compounds | 54 |
| 2.5 | Bonding in Metal Complexes | 60 |
| 2.5.1 | The Crystal Field Theory and Octahedral Complexes | 60 |
| 2.5.2 | The MO Theory and Octahedral Complexes | 70 |
| 2.5.3 | The Eighteen-Electron Rule | 74 |
| 2.5.4 | The Crystal Field Theory and Complexes of CN 4 | 75 |
| 2.6 | The Magnetism and Spectroscopy of Metal Complexes | 78 |
| 2.6.1 | The Electronic Spectra of Metal Complexes | 78 |
| 2.6.2 | Lanthanide Luminescence | 80 |
| 2.6.3 | The Magnetic Properties of Transitional Element Complexes | 81 |
| 2.7 | The Energetics of Metal Complex Formation | 83 |
| 2.7.1 | Equilibrium or Stability Constants | 83 |
| 2.7.2 | Hard and Soft Donors or Acceptors | 88 |
| 2.7.3 | The Chelate and Macrocyclic Effects | 89 |
| 2.8 | Reactions at Metal Centres | 90 |
| 2.8.1 | Thermodynamic and Kinetic Stability | 90 |
| 2.8.2 | Substitution Reactions at Metal Centres | 92 |
| 2.8.3 | Mechanisms of Substitution at Metal Centres | 93 |
| 2.9 | Redox Potentials | 96 |
| 2.10 | Conclusions | 99 |
| Chapter 3 Diagnostic Medicine | | 101 |
| 3.1 | Introduction | 101 |
| 3.2 | Anatomical Imaging | 103 |
| 3.2.1 | Magnetic Resonance Imaging Contrast Agents | 103 |
| 3.2.2 | X-ray Contrast Agents | 130 |
| 3.3 | Functional Imaging | 133 |
| 3.3.1 | Radiopharmaceuticals for Functional Imaging | 133 |
| 3.3.2 | Nuclear Medicine | 134 |
| 3.3.3 | Radiopharmaceuticals | 139 |
| 3.3.4 | Aspects of Technetium Chemistry | 141 |
| 3.3.5 | Blood-pool Imaging and Labelled Blood Cells | 152 |
| 3.3.6 | ^{99m} Tc SPECT Imaging Agents for Bone | 153 |
| 3.3.7 | Kidney Imaging | 156 |

| | | |
|--------|--|-----|
| 3.3.8 | Liver and Hepatobiliary System | 159 |
| 3.3.9 | Heart SPECT and PET Imaging | 161 |
| 3.3.10 | Brain Imaging | 169 |
| 3.3.11 | Tumors Abscesses and Hypoxia | 176 |
| 3.3.12 | Synthetic Approaches to Bifunctional ^{99m} Tc Radiopharmaceuticals | 185 |
| 3.4 | <i>In vitro</i> Applications | 199 |

Chapter 4 Therapeutic Medicine 201

| | | |
|-------|---|-----|
| 4.1 | The Use of Metal Compounds in Therapy | 201 |
| 4.2 | Chelation Therapy | 202 |
| 4.2.1 | Metal Sequestration | 202 |
| 4.2.2 | Macrocyclic Antibiotics | 203 |
| 4.2.3 | Metal Intoxication | 205 |
| 4.2.4 | Thalassaemia–Iron | 212 |
| 4.2.5 | Wilson Disease–Copper | 216 |
| 4.3 | Cancer Therapy | 218 |
| 4.3.1 | Metal Complexes in Cancer Therapy | 218 |
| 4.3.2 | Platinum and Palladium Anticancer Agents | 219 |
| 4.3.3 | Non-Platinum Anticancer Agents | 257 |
| 4.4 | Rheumatoid Arthritis | 283 |
| 4.4.1 | Introduction | 283 |
| 4.4.2 | Gold Chemistry | 284 |
| 4.4.3 | Gold Compounds for the Treatment of Rheumatoid Arthritis | 285 |
| 4.5 | Diabetes | 292 |
| 4.5.1 | Vanadium and Diabetes | 292 |
| 4.5.2 | Vanadium Chemistry | 292 |
| 4.5.3 | Vanadium Salts as Insulin Mimics | 293 |
| 4.5.4 | Vanadium Coordination Compounds as Insulin Mimics | 294 |
| 4.5.5 | Mechanism of Action of Vanadium Compounds | 297 |
| 4.6 | Cardiovascular System | 298 |
| 4.6.1 | <i>In vivo</i> Management of Gaseous Compounds | 298 |
| 4.6.2 | Superoxide Dismutase Mimics | 299 |
| 4.6.3 | Nitric Oxide Management | 306 |
| 4.7 | Therapeutic Radiopharmaceuticals | 309 |
| 4.7.1 | Radiation Therapy | 309 |
| 4.7.2 | α -Emitters | 309 |
| 4.7.3 | β -Emitters | 311 |
| 4.7.4 | Radiosensitisers | 321 |

| | |
|--|------------|
| Chapter 5 Metallopharmaceuticals Design | 324 |
| 5.1 Introduction | 324 |
| 5.2 Structure Activity Relationships | 324 |
| 5.2.1 Organic Molecules | 325 |
| 5.2.2 Metallopharmaceuticals | 327 |
| 5.3 Future Directions | 335 |
| Further Reading | 340 |
| Subject Index | 344 |